Abiopharma

🔍 Kihara James (Executive)

Company: ACADIA PHARMACEUTICALS INC (ACAD)

Report Date: 2026-04-05

Detailed Transactions and Holdings:

• Acquired 2,010 shares of Common Stock (Direct)
  Date: 2026-04-05 | Code: M | equity_swap_involved: 0 | shares_owned_after: 28,895.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 1,030 shares of Common Stock at $22.2 per share (Direct)
  Date: 2026-04-07 | Code: S | equity_swap_involved: 0 | shares_owned_after: 27,865.00 | transaction_form_type: 4 | Footnotes: F2, F3
• Sold 2,010 shares of Restricted Stock Units (Derivative)
  Date: 2026-04-05 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F4, F4

Footnotes:

• F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
• F2: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
• F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.07 to $22.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
• F4: The restricted stock units vest in four equal annual installments beginning April 5, 2023.